Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng E Chee

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Pitfalls in the diagnosis of primary amyloidosisCheng E Chee, Martha Q Lacy, Ahmet Dogan, et al.
Blood|July 14, 2011
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survivalJeremy T Larsen, Cheng E Chee, John A Lust, et al.
Blood|May 1, 2014
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort studyCheng E Chee, Aneel A Ashrani, Randolph S Marks, et al.
Blood|July 31, 2009
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee, Shaji Kumar, Dirk R Larson, et al.
Cancer|March 9, 2010
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423Cheng E Chee, James R Jett, Albert M Bernath, et al.
British Journal of Cancer|February 16, 2023
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trialsJerold Loh, Jiaxuan Wu, Jenny Chieng, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2024
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancerByoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, et al.
Targeted Oncology|April 15, 2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesCheng E Chee, Melissa Ooi, Soo-Chin Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with CancerAyumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Pitfalls in the diagnosis of primary amyloidosisCheng E Chee, Martha Q Lacy, Ahmet Dogan, et al.
Blood|July 14, 2011
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survivalJeremy T Larsen, Cheng E Chee, John A Lust, et al.
Blood|May 1, 2014
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort studyCheng E Chee, Aneel A Ashrani, Randolph S Marks, et al.
Blood|July 31, 2009
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee, Shaji Kumar, Dirk R Larson, et al.
Cancer|March 9, 2010
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423Cheng E Chee, James R Jett, Albert M Bernath, et al.
British Journal of Cancer|February 16, 2023
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trialsJerold Loh, Jiaxuan Wu, Jenny Chieng, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2024
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancerByoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, et al.
Targeted Oncology|April 15, 2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesCheng E Chee, Melissa Ooi, Soo-Chin Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with CancerAyumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 2